
INSM Earnings & Financial Statements
Insmed Incorporated
$144.46
+$24.66(+20.58%)
53
Overall
40
Value
58
Tech
63
Quality
Market Cap
$31.69B
Volume
14.40M
52W Range
$90.39 - $212.75
Target Price
$190.35
INSM earnings and financial statements: Insmed Incorporated's income statement, balance sheet and cash flow statement, annual and quarterly.
INSM Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $606.42M | $363.71M | $305.21M | $245.36M | $188.46M |
| Cost of revenue | $122.94M | $85.74M | $65.57M | $55.13M | $44.15M |
| Operating income | -$994.78M | -$878.25M | -$709.63M | -$457.32M | -$375.09M |
| EBITDA | -$1.18B | -$804.54M | -$644.71M | -$441.41M | -$383.65M |
| Net income | -$1.28B | -$913.77M | -$749.57M | -$481.53M | -$434.65M |
| EPS (diluted) | $-6.42 | $-5.57 | $-5.34 | $-3.91 | $-3.88 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $2.26B | $2.03B | $1.33B | $1.66B | $1.24B |
| Total liabilities | $1.53B | $1.74B | $1.66B | $1.57B | $833.04M |
| Shareholders’ equity | $738.98M | $285.38M | -$331.92M | $87.95M | $410.47M |
| Cash and equivalents | $510.44M | $555.03M | $482.37M | $1.07B | $716.78M |
| Long-term debt | $573.86M | $1.14B | $1.19B | $1.17B | $602.13M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$935.01M | -$683.88M | -$536.25M | -$400.44M | -$363.30M |
| Capital expenditure | -$32.56M | -$21.92M | -$13.29M | -$9.88M | -$7.29M |
| Free cash flow | -$967.58M | -$705.80M | -$549.53M | -$410.32M | -$370.59M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | INSM | $144.46 | +20.6% | 14.40M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |